{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:20:11Z","timestamp":1787934011273,"version":"build-2784847793"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To describe primary immunodeficiencies caused by gain-of-function (GOF) mutations of signal transducer and activator of transcription (STAT) genes, a group of genetically determined disorders characterized by susceptibility to infections and, in many cases, autoimmune manifestations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>GOF mutations affecting STAT1 result in increased STAT tyrosine phosphorylation and secondarily increased response to STAT1-signaling cytokines, such as interferons. In contrast, STAT3 hyperactivity is not usually related to hyperphosphorylation but rather to increased STAT3-mediated transcriptional activity. In both cases, heterozygous STAT1 and STAT3 GOF mutations trigger a distinct set of genes in target cells that lead to abnormal functioning of antimicrobial response and\/or autoimmunity and result in autosomal dominant diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Clinical manifestations of patients with STAT1 GOF are characterized by mucocutaneous candidiasis and recurrent lower tract respiratory infections. In addition, many patients have thyroiditis, type 1 diabetes mellitus, autoimmune cytopenias, cancer or aneurysms. Patients with germline STAT3 GOF mutations have an increased frequency of early-onset multiorgan autoimmunity (i.e. autoimmune enteropathy, type 1 diabetes mellitus, autoimmune interstitial lung disease and autoimmune cytopenias), lymphoproliferation, short stature and, less frequently, severe recurrent infections. Treatment options range from antimicrobial therapy, intravenous or subcutaneous immunoglobulin and immunosuppressive drugs. Some patients with STAT1 GOF disorder have undergone hematopoietic stem cell transplantation, although these have been difficult because of the underlying proinflammatory milieu from the mutation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000551","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T01:40:11Z","timestamp":1505439611000},"page":"711-717","source":"Crossref","is-referenced-by-count":35,"title":["Signal transducer and activator of transcription gain-of-function primary immunodeficiency\/immunodysregulation disorders"],"prefix":"10.1097","volume":"29","author":[{"given":"Filippo","family":"Consonni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Todaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Vairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Badolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231208","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1189\/jlb.5RI0516-237RR","article-title":"STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases","volume":"101","author":"Lorenzini","year":"2017","journal-title":"J Leukoc Biol"},{"key":"R2-20231208","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype: an international survey of 274 patients from 167 kindreds","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"R3-20231208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.12.010","article-title":"Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: presenting as treatment-resistant candidiasis and chronic lung disease","volume":"164","author":"Dotta","year":"2016","journal-title":"Clin Immunol"},{"key":"R4-20231208","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jaci.2013.01.052","article-title":"Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis","volume":"131","author":"Sampaio","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R5-20231208","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1100102","article-title":"STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis","volume":"365","author":"van de Veerdonk","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20231208","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0140-6736(12)60365-1","article-title":"Herpes in STAT1 gain-of-function mutation [corrected]","volume":"379","author":"T\u00f3th","year":"2012","journal-title":"Lancet"},{"key":"R7-20231208","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaci.2013.09.032","article-title":"Fatal combined immunodeficiency associated with heterozygous mutation in STAT1","volume":"133","author":"Sharfe","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R8-20231208","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1189\/jlb.0513250","article-title":"Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis","volume":"95","author":"Mizoguchi","year":"2014","journal-title":"J Leukoc Biol"},{"key":"R9-20231208","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10875-014-0111-7","article-title":"Orf infection in a patient with Stat1 gain-of-function","volume":"35","author":"Kilic","year":"2015","journal-title":"J Clin Immunol"},{"key":"R10-20231208","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","author":"Leiding","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R11-20231208","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-010-9480-8","article-title":"Novel STAT1 alleles in a patient with impaired resistance to mycobacteria","volume":"31","author":"Kristensen","year":"2011","journal-title":"J Clin Immunol"},{"key":"R12-20231208","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20110958","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J Exp Med"},{"key":"R13-20231208","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaci.2016.10.051","article-title":"Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations","volume":"140","author":"Tabellini","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R14-20231208","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12026-011-8226-x","article-title":"IL-17 signaling in host defense against Candida albicans","volume":"50","author":"Gaffen","year":"2011","journal-title":"Immunol Res"},{"key":"R15-20231208","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1002\/eji.201445344","article-title":"Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)","volume":"45","author":"Zheng","year":"2015","journal-title":"Eur J Immunol"},{"key":"R16-20231208","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1126\/science.1125676","article-title":"Type 1 interferons and the virus-host relationship: a lesson in d\u00e9tente","volume":"312","author":"Garc\u00eda-Sastre","year":"2006","journal-title":"Science"},{"key":"R17-20231208","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.4049\/jimmunol.165.7.3571","article-title":"Distinct requirements for IFNs and STAT1 in NK cell function","volume":"165","author":"Lee","year":"2000","journal-title":"J Immunol"},{"key":"R18-20231208","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.4049\/jimmunol.169.8.4279","article-title":"Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection","volume":"169","author":"Nguyen","year":"2002","journal-title":"J Immunol"},{"key":"R19-20231208","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2014.05.044","article-title":"Gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1): Chronic mucocutaneous candidiasis accompanied by enamel defects and delayed dental shedding","volume":"134","author":"Frans","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R20-20231208","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.gene.2016.04.006","article-title":"Common variable immunodeficiency, impaired neurological development and reduced numbers of T regulatory cells in a 10-year-old boy with a STAT1 gain-of-function mutation","volume":"586","author":"Kobbe","year":"2016","journal-title":"Gene"},{"key":"R21-20231208","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaci.2013.01.004","article-title":"Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival","volume":"131","author":"Romberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R22-20231208","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"Mechanisms of disease JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"R23-20231208","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MOH.0000000000000206","article-title":"Signal transducer and activator of transcription 3","volume":"23","author":"Forbes","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"R24-20231208","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T cell large granular lymphocyte leukemia","volume":"120","author":"Jerez","year":"2012","journal-title":"Blood"},{"key":"R25-20231208","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"key":"R26-20231208","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"N Engl J Med"},{"key":"R27-20231208","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nature06096","article-title":"Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome","volume":"448","author":"Minegishi","year":"2007","journal-title":"Nature"},{"key":"R28-20231208","first-page":"e23435","article-title":"STAT3 and the hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties","volume":"2","author":"Mogensen","year":"2013","journal-title":"JAKSTAT"},{"key":"R29-20231208","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2014-09-602763","article-title":"Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations","volume":"125","author":"Milner","year":"2015","journal-title":"Blood"},{"key":"R30-20231208","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ng.3040","article-title":"Activating germline mutations in STAT3 cause early-onset multi organ autoimmune disease","volume":"46","author":"Flanagan","year":"2014","journal-title":"Nat Genet"},{"key":"R31-20231208","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2014-04-570101","article-title":"Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3","volume":"125","author":"Haapaniemi","year":"2015","journal-title":"Blood"},{"key":"R32-20231208","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12026-007-0022-2","article-title":"IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity","volume":"38","author":"Ochs","year":"2007","journal-title":"Immunol Res"},{"key":"R33-20231208","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"key":"R34-20231208","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jaci.2012.11.054","article-title":"Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome","volume":"131","author":"Uzel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R35-20231208","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/MOP.0000000000000029","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases","volume":"25","author":"Verbsky","year":"2014","journal-title":"Curr Opin Pediatr"},{"key":"R36-20231208","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ajhg.2010.01.028","article-title":"Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease","volume":"86","author":"Lohr","year":"2010","journal-title":"Am J Hum Genet"},{"key":"R37-20231208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00058","article-title":"SOCS3, a major regulator of infection and inflammation","volume":"5","author":"Carow","year":"2014","journal-title":"Front Immunol"},{"key":"R38-20231208","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/eji.200737193","article-title":"Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function","volume":"37","author":"Pillemer","year":"2007","journal-title":"Eur J Immunol"},{"key":"R39-20231208","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.4049\/jimmunol.179.7.4313","article-title":"Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity","volume":"179","author":"Harris","year":"2007","journal-title":"J Immunol"},{"key":"R40-20231208","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10875-014-0038-z","article-title":"Elevated double negative T cells in pediatric autoimmunity","volume":"34","author":"Tarbox","year":"2014","journal-title":"J Clin Immunol"},{"key":"R41-20231208","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2141.2006.05993.x","article-title":"Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype","volume":"133","author":"Worth","year":"2006","journal-title":"Br J Haematol"},{"key":"R42-20231208","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.dib.2016.02.040","article-title":"Clinical and immunological data of nine patients with chronic mucocutaneous candidiasis disease","volume":"7","author":"Dotta","year":"2016","journal-title":"Data Brief"},{"key":"R43-20231208","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R44-20231208","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"(Suppl)","key":"R45-20231208","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jinf.2016.04.023","article-title":"Treatment options for chronic mucocutaneous candidiasis","volume":"72","author":"van de Veerdonk","year":"2016","journal-title":"J Infect"},{"key":"R46-20231208","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaci.2017.01.004","article-title":"Targeted strategies directed at the molecular defect: toward precision medicine for select primary immunodeficiency disorders","volume":"139","author":"Notarangelo","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R47-20231208","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12016-016-8591-2","article-title":"An update on the use of immunomodulators in primary immunodeficiencies","volume":"52","author":"Vignesh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R48-20231208","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrd4088","article-title":"Therapeutic modulators of STAT signalling for human diseases","volume":"12","author":"Miklossy","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"R49-20231208","first-page":"136","article-title":"Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors","volume":"1845","author":"Siveen","year":"2014","journal-title":"Biochim Biophys Acta"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201712000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T05:01:26Z","timestamp":1702011686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201712000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000551","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}